Phase II trial of oral idarubicin in advanced non-small cell lung cancer (NSCLC)

Andrea Ardizzoni, Paolo Pronzato, Lazzaro Repetto, Mario De Palma, Luciano Canobbio, Marcella Gulisano, Vittorio Fusco, Riccardo Rosso, Franco Ganzina

Research output: Contribution to journalArticlepeer-review

Abstract

The antitumoral activity and toxicity of a new daunorubicin analog (4-demethoxydaunorubicin, IMI30, Idarubicin) was tested in 20 consecutive patients with non-small cell lung cancer mostly pretreated with chemotherapy. The drug was administered orally at a dose of 15 mg/m2 for three days every 3-4 weeks. There were no clinical responses. Hematological and nonhematobgical toxicities were mild.

Original languageEnglish
Pages (from-to)409-411
Number of pages3
JournalCancer Investigation
Volume6
Issue number4
DOIs
Publication statusPublished - 1988

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Fingerprint Dive into the research topics of 'Phase II trial of oral idarubicin in advanced non-small cell lung cancer (NSCLC)'. Together they form a unique fingerprint.

Cite this